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1576cholesterol [LDL-C] at base-
line, 71 mg/dl/1.81 mmol/l),
with the addition of ERN to
simvastatin therapy during a 3-
year mean follow-up period was
associated with a 25% increase
in HDL-C, a further 12% re-
duction in LDL-C, and a 30%
additional reduction in triglyc-
eride levels (1). However, the
trial was stopped 18 months
earlier than planned because
a pre-deﬁned lack of efﬁcacy
boundary had been crossed, so
the addition of ERN failed to
further reduce the incidence of
CV events. This report focuseson the effect of LDL-lowering therapy (simvastatin with or
without ezetimibe), plus ERN versus LDL-lowering
therapy alone on Lp(a), apoA-1, and apoB, and the rela-
tionships of their levels (at baseline and on-treatment) to
CV outcomes.
First, our aim was to evaluate the impact of intensive
LDL-lowering therapy alone or in combination with ERN
on apoA-1, apoB, and Lp(a). Second, our aim was to assess
whether apoA-1, apoB, or Lp(a) levels are predictive of CV
events in either group at baseline or in-trial. Third, our aim
was to assess whether a subgroup of participants, deﬁned by
baseline apolipoprotein values, who demonstrated clinical
beneﬁts from niacin therapy could be identiﬁed.Figure 1
Comparison of the AIM-HIGH Trial and Framingham
Baseline Lp(a) Distribution
Histogram of baseline lipoprotein(a) [Lp(a)] [nmol/l] for each study. Lp(a)
distributions are compared using the Wilcoxon rank sum test.Methods
Study population. The AIM-HIGH trial population and
baseline characteristics were previously described (1). The
primary composite outcome was death from coronary
disease, nonfatal myocardial infarction, ischemic stroke,
hospitalization for acute coronary syndrome, or symptom-
driven coronary or cerebrovascular revascularization. In this
paper, we evaluated only participants who were prescri-
bed statin therapy prior to the trial (n ¼ 3,196; 94% of
randomized subjects). Per protocol, samples for apolipo-
protein analyses were collected at baseline and 1-year post-
baseline.
Analytical measurements. Analyses of apoA-1 and apoB
were performed using Siemens reagent on a Seimens BNII
nephelometer (Seimens Healthcare Diagnostics, Newark,
Delaware). Analysis of Lp(a) was performed by a mono-
clonal antibody-based enzyme-linked immunoadsorbent
assay (ELISA) method developed in the laboratory, as
previously reported (2), which was considered the gold
standard method for measuring Lp(a).
Statistical analyses. Baseline Lp(a) values were compared
with the Framingham study using the Wilcoxon rank sum
test. Treatment differences for change from baseline are
presented as least-square means from generalized linearmodels, including treatment, sex, diabetes, baseline imbal-
ances, and baseline apolipoprotein as covariates. Percent
change is calculated from these results. Relationships between
apolipoproteins and cardiovascular events were examined
using the primary study endpoint.
Hazard ratios (HRs) examining the relationship between
baseline values and events were calculated from Cox propor-
tional hazards survival models, adjusted for sex, diabetes, and
baseline ApoA-1. Heterogeneity of the relationship between
baseline values and events across randomization assignment
was assessed by adding value-by-treatment interaction terms.
Subgroups were examined using quartiles for Lp(a) and ter-
tiles otherwise. Differences in the effect of treatment across
baseline levels of Lp(a) and apoB/apoA-1 were tested by
adding a level-by-treatment interaction term to the models.
The relationships between on-study standardized apoli-
poprotein levels and events were evaluated using Cox
proportional hazards survival models with time-dependent
covariates, adjusted for sex, diabetes, baseline ApoA-1, and
HDL2-C. Subjects who reached the primary endpoint prior
to 1 year (scheduled collection) were excluded from this
analysis.
Two-sided p values <0.05 were considered signiﬁcant.
No adjustments were made for multiple testing. The SAS
Version 9.2 (SAS Institute, Inc., Cary, North Carolina) was
used for all statistical analyses.Results
Participants and baseline characteristics. The mean age
of study participants was 63.7 years (85.2% were men and
92.2% were Caucasian). Baseline demographic and clinical
characteristics were similar in the 2 groups randomized to
either control LDL-lowering therapy or LDL-lowering
therapy plus ERN, except mean body mass index (BMI),
Table 1 Least-Square Mean Values at Baseline, Year 1, and Percent Change in Apo and Lp(a)*
Test
Statin Plus Placebo Statin Plus ERN
Diff. in Percent
Changez vs. PlaceboN Base Year 1 Percent Changey N Base Year 1 Percent Changey
ApoB (mg/dl) 1,443 82.0 79.6 2.9 1,424 81.8 71.3 12.8 -10.7x
ApoA-1 (mg/dl) 1,443 126.2 128.6 1.9 1,424 125.6 134.5 7.1 4.7x
ApoB/ApoA-1 ratio 1,459 0.7 0.6 6.6 1,440 0.7 0.5 19.4 13.6
Lp(a) (nmol/l) 1,440 78.3 73.7 5.9 1,427 80.2 63.4 21.0 -19.4{
Log Lp(a) (nmol/l) 1,440 3.5 3.4 3.4 1,427 3.5 3.2 9.9 9.7{
*Participants with measurements at baseline and 1-year post-baseline are included. Baseline analysis of covariance (ANCOVA) models adjusted for sex and diabetes; year 1 ANCOVA models adjusted for sex,
diabetes, ApoA-I, and high-density lipoprotein 2 cholesterol (HDL2-C) (imbalanced at baseline). yPercent change from baseline to year 1 post-baseline. zBased on ANCOVA. xp < 0.001. {p < 0.05 for
comparison of percent change by treatment.
Apo ¼ apolipoprotein; Base ¼ baseline value; Diff ¼ difference; ERN ¼ extended-release niacin; N ¼ number of patients with data; Percent Change ¼ change from baseline to year 1.
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p ¼ 0.003).
Baseline apolipoprotein and Lp(a) levels. Consistent
with participant selection criteria, mean apoB and apoA-1
levels were low. However, the median level of Lp(a) (33.8
nmol/l) was elevated as compared with the median Lp(a)
level (20 nmol/l) of healthy, predominantly Caucasian
adults from Framingham (3). Comparison of the Lp(a)
distribution of the AIM-HIGH trial with the Framingham
cohort, determined by the same ELISA method, indicates
that the Lp(a) distribution at baseline of the AIM-HIGH
trial participants was shifted to higher levels (Fig. 1).
Nearly 30% of the AIM-HIGH trial cohort at baseline had
Lp(a) levels >100 nmol/l compared with 20% of
Framingham.
Apolipoprotein and Lp(a) levels after 1 year of treatment.
In the ERN group and the placebo group, apoB decreased
by 13% and 3%, apoA-1 increased by 7% and 2%, and the
apoB/apoA-1 ratio decreased by 19% and 7%, respectively
(Table 1). For the ERN group, Lp(a) decreased by 21%
overall with 20%, 39%, and 64% decreases in the 50th, 75th,
and 90th Lp(a) percentiles, respectively. An overall decrease
of 6% for Lp(a) was also observed in the placebo group; thus,
the overall least-square mean decrease in Lp(a) due to ERN
was 19%.
Baseline apolipoprotein and Lp(a) levels and subsequent
CV events. Baseline levels of apoB and apoB/apoA-1
were only associated with CV events in the placebo and
not in the ERN group, but the treatment interactions
were not signiﬁcant. Lp(a) was signiﬁcantly associatedTable 2 Association Between 1 SD Increase in Baseline* Apo, Lp(a)
Test SD
Statin Plus Placebo
HRy 95% CI p
ApoB (mg/dl) 18.3 1.17 1.03 1.33 0
ApoA-1 (mg/dl) 16.2 0.94 0.83 1.07 0
ApoB/apoA-1 ratio 0.16 1.19 1.03 1.36 0
Lp(a) (nmol/l) 88.7 1.22 1.10 1.35 <0
Log Lp(a) (nmol/l) 1.55 1.24 1.08 1.43 0
*Proportional hazards models adjusted for stratiﬁcation factors and ApoA-1. yHR is the increase in risk
CI ¼ conﬁdence interval; CV ¼ cardiovascular; HR ¼ hazard ratio; Int. ¼ interaction between randomiwith CV events and exhibited the highest hazard ratios
in both treatment groups (Table 2). As shown in Figures 2
and 3, similar hazard ratios for the second, third, and
fourth Lp(a) quartiles were observed in the placebo and
ERN groups (1.19, 1.37, and 1.87 vs. 1.19, 1.37, and 1.90,
respectively). Kaplan-Meier estimates of the percentages
of participants free from a primary event by baseline Lp(a)
quartile for both treatment groups are shown in Figures 2
and 3.
1-year apolipoprotein and Lp(a) levels and CV events
within treatment groups. A 1 SD (0.16) higher apoB/
apoA-1 ratio in the placebo group was associated with
a 21% higher risk of a primary event (p ¼ 0.031), and a 1 SD
(1.55) higher log Lp(a) was associated with a 21% increase
in CV event risk (HR: 1.21; p ¼ 0.017). For the ERN
group, apoB/apoA-1 at 1 year was not associated with CV
event risk (HR: 1.06; p ¼ 0.50), whereas the log Lp(a) level
did remain related to CV event risk (HR: 1.18; p ¼ 0.028)
(Table 3).
Comparison of on-treatment apolipoprotein and Lp(a)
levels and CV events between treatment groups. Overall,
and within each quartile of baseline Lp(a), a similar numbers
of events occurred in the placebo and ERN groups; for the
highest Lp(a) quartile, there were 78 events in the placebo
group versus 83 in the ERN group. There was no signiﬁcant
difference in primary event rate between the placebo
and ERN group for any quartile of baseline Lp(a)
(p ¼ 0.994 for treatment effect by Lp(a) quartile) despite
greater decreases in Lp(a) for those taking ERN as
compared to placebo. Comparing baseline quartiles of Lp(a), and CV Events
Statin Plus ERN
Int.
p ValuezValue HRy 95% CI p Value
.018 1.11 0.97 1.27 0.124 0.905
.373 0.93 0.81 1.07 0.337 0.82
.016 1.13 0.99 1.30 0.078 0.87
.001 1.16 1.04 1.28 0.006 0.646
.002 1.25 1.10 1.42 0.001 0.987
of an increase of 1 SD. zTest for heterogeneity of treatment effect across values.
zation assignment and value; SD ¼ standard deviation; other abbreviations as in Table 1.
Figure 2
Time to First Cardiovascular Event for Statin Plus
Placebo Arm by Baseline Lp(a) Quartile
Kaplan-Meier curves show time to ﬁrst cardiovascular event for quartiles of
baseline Lp(a) (nmol/L) in patients randomized to low-density lipoprotein (LDL)-
lowering therapy plus placebo. Hazard ratio (HR) and 95% conﬁdence interval (CI)
are based on Cox proportional hazards survival regression, including terms for sex
and diabetes. Abbreviations as in Figure 1.
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quartile was 0.98 (95% conﬁdence interval [CI]: 0.73 to
1.32); similarly, there was no effect of ERN treatment in any
of the lower quartiles. From this analysis, it is clear that evenFigure 3
Time to First Cardiovascular Event for Statin Plus
Niacin Arm by Baseline Lp(a) Quartiles
Kaplan-Meier curves show time to ﬁrst cardiovascular event for quartiles of
baseline Lp(a) (nmol/L) in patients randomized to LDL-lowering therapy plus
niacin. The HR and 95% CI are based on Cox proportional hazards survival model
of regression, including terms for sex and diabetes. Abbreviations as in
Figures 1 and 2.the on-study ERN group in the highest Lp(a) quartile,
which was >125 nmol/l, did not beneﬁt from the addition
of niacin to the statin-based therapy.
Because niacin increases apoA-1, lowers apoB, and
consequently lowers apoB/apoA-1, we also evaluated the
HR for apoB/apoA-1 tertiles at baseline. Within the highest
tertile of apoB/apoA-1, there was no detectable reduction in
CV event risk with ERN.
Discussion
The principal ﬁndings of our study were at 1 year, compared
to the placebo group, those randomized to ERN had
signiﬁcantly higher apoA-I levels, a lower apoB/apoA-I
ratio, and lower levels of Lp(a). Despite these favorable
changes with ERN, apoA-1, apoB, and Lp(a) variables did
not identify any subgroup of participants who beneﬁted from
ERN therapy. Baseline and on-study Lp(a) predicted CV
events in both treatment groups.
Lp(a) levels and the prediction of CV events. A partic-
ularly interesting result of the AIM-HIGH trial is that
baseline and on-study Lp(a) predicted CV events in both the
control LDL-lowering therapy plus placebo and LDL-
lowering therapy plus ERN arms, suggesting that Lp(a)
still contributes to residual CV risk in patients achieving
target LDL-C levels with statin therapy. These results
contradict our earlier post-hoc analysis of the Familial
Atherosclerosis Treatment Study, in which men with
coronary artery disease and elevated LDL-C, Lp(a) corre-
lated strongly with both baseline CV disease severity and
progression in the placebo group (4). However, in those
receiving statins, in whom LDL-C was reduced substan-
tially, but Lp(a) levels were unaffected, Lp(a) levels were no
longer associated with risk of CV events or progression.
Meta-analysis has demonstrated a consistent, continuous,
and independent association between Lp(a) level and CV
risk, without indicating a speciﬁc threshold (5). Despite the
desire for a speciﬁc clinical risk threshold (6) based on meta-
analyses and consistent with our analysis of Lp(a) quartiles in
the AIM-HIGH trial, CV disease risk continues to increase
at high levels of Lp(a). Our study also indicates that ERN is
not associated with clinical beneﬁt, even for those with the
highest baseline Lp(a) levels.
Causality of Lp(a) for CV disease. Several studies have
provided strong support for the causality of elevated Lp(a)
for premature coronary artery disease (7,8). Further sup-
port for this causality depends on demonstrating that
reduction of elevated Lp(a) reduces CV events. Jaeger et al.
(9) treated patients with CV disease and elevated Lp(a)
>95th percentile with lipid-lowering drugs to lower
LDL-C. Subsequently, these patients underwent LDL
apheresis, which dramatically lowered Lp(a) by 73%. The
rate of major adverse CV events was reduced in patients
with either further substantial or minimal LDL reduction,
suggesting that lowering Lp(a) was beneﬁcial. Participants
in the AIM-HIGH trial treated with ERN had only
Table 3 Association Between a 1 SD Increase in Apo and Lp(a) Levels After 1 Year of Treatment* and CV Events
Test SD
Statin Plus Placebo Statin Plus ERN
Int.
p ValuezHRy 95% CI p Value HRy 95% CI p Value
ApoB (mg/dl) 18.3 1.15 0.98 1.35 0.092 1.04 0.88 1.23 0.648 0.457
ApoA-1 (mg/dl) 16.2 0.89 0.75 1.06 0.185 1.03 0.86 1.23 0.734 0.717
ApoB/apoA-1 ratio 0.16 1.21 1.02 1.43 0.031 1.06 0.90 1.25 0.499 0.452
Lp(a) (nmol/L) 88.7 1.23 1.07 1.42 0.004 1.18 1.00 1.39 0.048 0.624
Log Lp(a) (nmol/L) 1.55 1.21 1.03 1.42 0.017 1.18 1.02 1.36 0.028 0.647
*Proportional hazards models adjusted for stratiﬁcation factors ApoA-1 and HDL2-C. yHR is the increase in risk of an increase of 1 SD. zTest for heterogeneity of treatment effect across values.
Abbreviations as in Tables 1 and 2.
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and no reduction in CV events Although it is possible
that the between-group difference in Lp(a) levels was too
small to detect a beneﬁt, a therapeutic intervention that
lowers Lp(a) more effectively and selectively would be
a stronger test of the hypothesis that Lp(a) reduction
decreases CV events.Conclusions
The AIM-HIGH trial demonstrated that Lp(a) contrib-
utes to residual CV risk in patients who achieved target
LDL-C levels with statin therapy. We have further
observed that favorable changes in apoliproteins and Lp(a)
from ERN did not result in CV event reduction. It is
possible that the relatively modest differences between the
treatment groups may have been insufﬁcient to cause
a reduction in CV risk over the 3-year treatment study.
The much larger HPS-2–THRIVE (Heart Protection
Study-2–Treatment of HDL to Reduce the Incidence of
Vascular Events) clinical trial, performed in more than
25,000 subjects, appears to conﬁrm the lack of clinical
beneﬁt of niacin added to LDL-lowering therapy on CV
outcomes observed in the AIM-HIGH trial (10).
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